Press Release
18 December 2024 07:00:00 CET

Neola Medical's CEO shares 2024 achievements in Winter Investor Letter

As 2024 comes to an end, Neola Medical highlights a year of significant advancements including the company's transition from technical verification phase to clinical validation phase, preparing for clinical studies on preterm born babies.

"In 2024, we reached two significant milestones that are essential for our upcoming FDA application: securing the CB certificate and successfully completing the Human Factors Validation study with nurses in the U.S. These accomplishments mark our transition from the technical verification to the clinical validation phase, preparing for our first clinical study on preterm born babies with our continuous lung monitoring device, Neola®.", says CEO Hanna Sjöström.

Read more about the latest news in the investor letter winter 2024, attached to this press release and available on the company's website www.neolamedical.com

For further information, contact:
Hanna Sjöström, CEO
e-mail: hanna.sjostrom@neolamedical.com

About Neola Medical
Neola Medical AB (publ) develops revolutionizing medical technology device for non-invasive continuous lung monitoring and real-time alerts of life-threatening lung complications of preterm born infants. Immediate detection of complications provides the possibility of early treatment, improved health care and healthier lives for preterm born infants. The patented cutting-edge technology is developed at Lund University in Sweden and based on a spectroscopic method that measures lung volume changes and oxygen gas concentration. Neola Medical is building on a historic Swedish legacy of medical technology innovation and invaluable contributions to global health care. The company was founded in 2016 and is listed on NASDAQ First North Growth Market (ticker: NEOLA). Read more at www.neolamedical.com. The company's Certified Adviser is FNCA Sweden AB.

Attachments
Neola Medical's CEO shares 2024 achievements in Winter Investor Letter
Neola Medical Investor Letter Winter 2024